Publication Name	World Journal of Clinical Oncology
Manuscript ID	19964
Country	United Kingdom

Received	2015-05-27 10:08
Peer-Review Started	2015-05-29 08:28
To Make the First Decision	2015-06-18 15:11
Return for Revision	2015-06-25 16:38
Revised	2015-07-08 21:00
Second Decision	2015-07-24 11:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-08-03 15:54
Articles in Press	2015-08-03 15:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-28 15:12
Publish the Manuscript Online	2015-10-13 10:26

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Modulators of alternative splicing as novel therapeutics in cancer
Manuscript Source	Invited Manuscript
All Author List	Sebastian Oltean
Funding Agency and Grant Number
Corresponding Author	Sebastian Oltean, MD, PhD, School of Physiology and Pharmacology, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, United Kingdom. sebastian.oltean@bristol.ac.uk
Key Words	Novel cancer therapeutics; Splicing switching oligonucleotides; Alternative splicing; Small molecules; Splicing modulators
Core Tip	Genome-wide studies have recently shown that more than 90% of genes are alternatively spliced in humans. This makes alternative splicing (AS) one of the main drivers of proteomic diversity. Numerous splice isoforms have been described to be associated with cancer. Additionally several splice factors have been shown to have oncogene or tumour suppressors activities. Beside the implications for cancer pathogenesis, de-regulated AS is recognized as one of the novel areas of cell biology where therapeutic manipulations may be designed. This editorial discusses the possibilities of manipulation of AS for therapeutic benefit in cancer.
Publish Date	2015-10-13 10:26
Citation	Oltean S. Modulators of alternative splicing as novel therapeutics in cancer. World J Clin Oncol 2015; 6(5): 92-95
URL	http://www.wjgnet.com/2218-4333/full/v6/i5/92.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i5.92

Full Article (PDF)	WJCO-6-92.pdf
Full Article (Word)	WJCO-6-92.doc
Manuscript File	19964-Review.docx
Answering Reviewers	19964-Answering reviewers.pdf
Audio Core Tip	19964-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	19964-Conflict-of-interest statement.pdf
Copyright License Agreement	19964-Copyright assignment.pdf
Peer-review Report	19964-Peer-review(s).pdf
Scientific Misconduct Check	19964-Scientific misconduct check.pdf
Scientific Editor Work List	19964-Scientific editor work list.pdf